Salem Almaani

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease

Laura Mariani, Andrew S. Bomback, Pietro A. Canetta et al. · American Journal of Kidney Diseases · 2018 · 131 citations · Full text

Glomerular Disease, Glomerulonephritis, Hemodialysis +10

Urinary Single-Cell Profiling Captures the Cellular Diversity of the Kidney

Amin Abedini, Yuan Zhu, Shatakshee Chatterjee et al. · Journal of the American Society of Nephrology · 2021 · 106 citations · Full text

Health-related quality of life in glomerular disease

Pietro A. Canetta, Jonathan P. Troost, Shannon Mahoney et al. · Kidney International · 2019 · 59 citations · Full text

Glomerular Disease, Glomerulonephritis, Hemodialysis +9